Zynerba Pharmaceuticals Gestione

Gestione criteri di controllo 3/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Armando Anido

Amministratore delegato

US$1.9m

Compenso totale

Percentuale dello stipendio del CEO	33.6%
Mandato del CEO	9yrs
Proprietà del CEO	1.9%
Durata media del management	6.8yrs
Durata media del Consiglio di amministrazione	8.2yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Armando Anido rispetto agli utili di Zynerba Pharmaceuticals?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2023	n/a	n/a	-US$38m
Mar 31 2023	n/a	n/a	-US$37m
Dec 31 2022	US$2m	US$633k	-US$35m
Sep 30 2022	n/a	n/a	-US$36m
Jun 30 2022	n/a	n/a	-US$38m
Mar 31 2022	n/a	n/a	-US$38m
Dec 31 2021	US$2m	US$603k	-US$37m
Sep 30 2021	n/a	n/a	-US$38m
Jun 30 2021	n/a	n/a	-US$37m
Mar 31 2021	n/a	n/a	-US$47m
Dec 31 2020	US$1m	US$585k	-US$51m
Sep 30 2020	n/a	n/a	-US$52m
Jun 30 2020	n/a	n/a	-US$45m
Mar 31 2020	n/a	n/a	-US$36m
Dec 31 2019	US$1m	US$568k	-US$33m
Sep 30 2019	n/a	n/a	-US$30m
Jun 30 2019	n/a	n/a	-US$36m
Mar 31 2019	n/a	n/a	-US$37m
Dec 31 2018	US$2m	US$568k	-US$40m
Sep 30 2018	n/a	n/a	-US$40m
Jun 30 2018	n/a	n/a	-US$41m
Mar 31 2018	n/a	n/a	-US$37m
Dec 31 2017	US$2m	US$552k	-US$32m
Sep 30 2017	n/a	n/a	-US$31m
Jun 30 2017	n/a	n/a	-US$28m
Mar 31 2017	n/a	n/a	-US$26m
Dec 31 2016	US$901k	US$536k	-US$23m

Compensazione vs Mercato: La retribuzione totale di Armando ($USD 1.88M ) è superiore alla media delle aziende di dimensioni simili nel mercato UK ($USD 354.57K ).

Compensazione vs guadagni: La retribuzione di Armando è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Armando Anido (65 yo)

9yrs

Mandato

US$1,881,402

Compensazione

Mr. Armando Anido, MBA, has been the Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, Inc. since October 2014. Mr. Anido has been an Independent Director of SCYNEXIS, Inc. since January 21,...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Armando Anido	Chairman & CEO	9yrs	US$1.88m	1.94% $ 1.3m
Terri Sebree	President	9yrs	US$1.38m	1.18% $ 775.1k
James Fickenscher	CFO & VP of Corporate Development (Leave of Absence)	7.1yrs	US$1.26m	0.75% $ 491.5k
Kenneth Jones	VP, Corporate Controller & Interim CFO	6.6yrs	Nessun dato	0.17% $ 111.2k
Albert Parker	Chief Legal Officer & Corporate Secretary	1.7yrs	Nessun dato	0.45% $ 295.1k
Joseph Apostolico	Vice President of Human Resources	5.6yrs	Nessun dato	Nessun dato

6.8yrs

Durata media

59yo

Età media

Gestione esperta: Il team dirigenziale di 0M40 è esperto e expertise (durata media dell'incarico 6.8 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Armando Anido	Chairman & CEO	9yrs	US$1.88m	1.94% $ 1.3m
Kenneth Moch	Independent Director	8.2yrs	US$107.50k	0.15% $ 98.5k
Daniel Kisner	Independent Director	8.2yrs	US$105.00k	0.15% $ 98.5k
Warren Cooper	Lead Independent Director	8.2yrs	US$135.00k	0.15% $ 98.5k
John Butler	Independent Director	5.5yrs	US$102.50k	0.16% $ 105.0k
William Federici	Independent Director	8.2yrs	US$110.00k	0.15% $ 98.5k
Steven Siegel	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Randi Hagerman	Member of Scientific Advisory Board	8yrs	Nessun dato	Nessun dato
Elizabeth Berry-Kravis	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Nicole Tartaglia	Member of Scientific Advisory Board	7yrs	Nessun dato	Nessun dato
Pamela Stephenson	Independent Director	4.7yrs	US$100.00k	0.15% $ 98.5k
Craig Erikson	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato

8.2yrs

Durata media

65yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 0M40 sono considerati esperti (durata media dell'incarico 8.2 anni).

Zynerba Pharmaceuticals Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Zynerba Pharmaceuticals, Inc., Annual General Meeting, Jul 27, 2023

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Recent updates

Zynerba Pharmaceuticals, Inc. acquired Epygenix Therapeutics, Inc for $680 million.

Zynerba Pharmaceuticals Files Form 15

Zynerba Pharmaceuticals, Inc.(NasdaqGM:ZYNE) dropped from NASDAQ Composite Index

Harmony Biosciences Holdings, Inc. (NasdaqGM:HRMY) completed the acquisition of Zynerba Pharmaceuticals, Inc. (NasdaqCM:ZYNE).

Zynerba Pharmaceuticals, Inc.(NasdaqCM:ZYNE) dropped from S&P TMI Index

New minor risk - Profitability

Zynerba Pharmaceuticals Provides Nasdaq Compliance Update

New major risk - Financial position

Zynerba Pharmaceuticals, Inc., Annual General Meeting, Jul 27, 2023

Forecast to breakeven in 2025

Zynerba Pharmaceuticals Gets an Additional 180 Calendar Day Period, or Until October 30, 2023 to Regain Compliance with the Bid Price Rule

Insufficient new directors

Insufficient new directors

Zynerba Pharmaceuticals Announces Update on Reconnect, the Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome

Zynerba Pharmaceuticals Announces Positive Long-Term Data from Phase 2 Inspire Trial in 22Q11.2 Deletion Syndrome At the Annual Meeting of the American College of Neuropsychopharmacology

Insufficient new directors

Zynerba Pharmaceuticals, Inc. Announces Publication of Data from Phase 3 CONNECT-FX Study of Zygel(TM) in the Journal of Neurodevelopmental Disorders

Zynerba Pharmaceuticals Receives a Deficiency Letter from Nasdaq

Zynerba Pharmaceuticals, Inc. Announces Issuance of New U.S. Patent for Zygel™ for the Treatment of 22Q11.2 Deletion Syndrome

Zynerba Pharmaceuticals Presents Positive Data from Phase 2 Inspire Trial in 22Q11.2 Deletion Syndrome At the National Organization for Rare Disorders (Nord) Rare Diseases and Orphan Products Breakthrough Summit

Zynerba Pharmaceuticals Announces Positive Top Line Results from Open-Label Phase 2 INSPIRE Trial of Zygel™ in 22q11.2 Deletion Syndrome

Insufficient new directors

Zynerba Pharmaceuticals, Inc. Presents Data on Zygel™ at the American Society of Clinical Psychopharmacology Annual Meeting

Zynerba Pharmaceuticals, Inc. Presents Long-Term Safety and Efficacy Data of Zygel™ in Children and Adolescents with Fragile X Syndrome At the International Society for Autism Research Annual Meeting

Insufficient new directors

Zynerba Pharmaceuticals, Inc., Annual General Meeting, Jun 14, 2022

Insufficient new directors

Insufficient new directors

Zynerba Pharmaceuticals, Inc. Announces European Commission Grants Orphan Drug Designation for Zygel™ in Fragile X Syndrome

Zynerba Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 2 Trial of Zygel in 22Q11.2 Deletion Syndrome

Zynerba Pharmaceuticals, Inc. Announces Executive Changes

Zynerba Pharmaceuticals Announces Clinical Development Updates for FXS, ASD, 22q and DEE

Zynerba Pharmaceuticals Initiates RECONNECT, a Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome

Zynerba Pharmaceuticals Announces Publication of Results of Phase 2 BELIEVE Open-Label Study of Zygel™ in Children and Adolescents with Developmental and Epileptic Encephalopathies (DEE) in JAMA Network Open

Pomerantz LLP and The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement Against Zynerba Pharmaceuticals, Inc

Forecast to breakeven in 2025

Zynerba Pharmaceuticals, Inc. Receives Guidance from the U.S. Food and Drug Administration on Confirmatory Phase 3 Trial of Zygel in Patients with Fragile X Syndrome

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media